Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Net Margin (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Net Margin for 13 consecutive years, with 478.31% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin rose 55930.0% year-over-year to 478.31%; the TTM value through Mar 2026 reached 640.81%, down 243143.0%, while the annual FY2025 figure was 764.01%, 260994.0% down from the prior year.
  • Net Margin hit 478.31% in Q1 2026 for Agios Pharmaceuticals, up from 541.09% in the prior quarter.
  • Across five years, Net Margin topped out at 10574.69% in Q3 2024 and bottomed at 1471.24% in Q1 2023.
  • Average Net Margin over 4 years is 120.58%, with a median of 1015.79% recorded in 2024.
  • Year-over-year, Net Margin soared 1180896bps in 2024 and then plummeted -1137774bps in 2025.
  • Agios Pharmaceuticals' Net Margin stood at 1350.7% in 2023, then skyrocketed by 33bps to 899.56% in 2024, then skyrocketed by 40bps to 541.09% in 2025, then increased by 12bps to 478.31% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 478.31%, 541.09%, and 803.05% for Q1 2026, Q4 2025, and Q3 2025 respectively.